Centaurus Financial, Inc. Exelixis, Inc. Transaction History

Centaurus Financial, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 15, 2019	SELL	$18.93 - $24.75 $2,044 - $2,673	-108 Closed	0 $0
Q1 2019 Jul 01, 2019	SELL	$19.6 - $24.76 $86,475 - $109,241	-4,412 Reduced 97.61%	108 $4.52 Million
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $88,592 - $111,915	4,520 New	4,520 $108,000
Q3 2018 Nov 05, 2018	SELL	$15.87 - $22.4 $221,227 - $312,256	-13,940 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$18.56 - $22.45 $258,726 - $312,953	13,940 New	13,940 $300,000

500

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.